Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer
Translational Breast Cancer Research · 2023-04 · 4 · 10-10
DOI: 10.21037/tbcr-23-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2023-04. Verfasst von Yang Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fifth Medical Centre of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Fifth Medical Centre of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
- Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Oncology, The First Hospital of China Medical Hospital, Shenyang, China.
- Department of Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China.
- Department of Breast Cancer, Jiangsu Province Hospital & The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zitieren
APA
Yuan, Y., Zhang, S., Wang, T., Wang, B., Wang, S., Shi, J., Sun, T., Yin, Y., Ouyang, Q., Li, J., Wen, Y., Zhang, L., & Jiang, Z. (2023). Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer. Translational Breast Cancer Research, 4, 10-10. https://doi.org/10.21037/tbcr-23-9
Vancouver
Yuan Y, Zhang S, Wang T, Wang B, Wang S, Shi J, et al. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer. Translational Breast Cancer Research. 2023;4:10-10. doi:10.21037/tbcr-23-9
BibTeX
@article{Yuan2023,
author = {Yuan, Yang and Zhang, Shaohua and Wang, Tao and Wang, Biyun and Wang, Shusen and Shi, Jing and Sun, Tao and Yin, Yongmei and Ouyang, Quchang and Li, Jianbin and Wen, Yi and Zhang, Lijun and Jiang, Zefei},
title = {Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer},
journal = {Translational Breast Cancer Research},
year = {2023},
volume = {4},
pages = {10--10},
doi = {10.21037/tbcr-23-9}
}
EUVIMED